Simple bioequivalence criteria: Are they relevant to critical dose drugs? Experience gained from cyclosporine

Therapeutic Drug Monitoring

Volumn 19, Issue 4, 1997, Pages 375-381

  Johnston, Atholl ^a   Keown, Paul A ^b   Holt, David W ^c  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Bioequivalence; Clinical trials; Critical dose drugs; Cyclosporine; Therapeutic equivalence

Indexed keywords

CYCLOSPORIN A; GELATIN;

AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG FORMULATION; DRUG RELEASE; FOOD AND DRUG ADMINISTRATION; FOOD DRUG INTERACTION; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

AREA UNDER CURVE; CHEMISTRY, PHARMACEUTICAL; CLINICAL TRIALS; CYCLOSPORINE; FOOD-DRUG INTERACTIONS; GUIDELINES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; THERAPEUTIC EQUIVALENCY; TIME FACTORS; TRANSPLANTATION;

EID: 0031423966     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199708000-00002     Document Type: Article

References (65)

1. Holt DW. Digoxin bioavailability. Lancet 1978;II:1103.
2. Eadie MJ, Sutherland JM, Tyrer JH. Dilantin overdosage. Med J Aust 1968;2:515.
3. Tyrer JH, Eadie MJ, Sutherland JM, Hooper WD. Outbreak of anticonvulsant intoxication in an Australian city. BMJ 1970;2:271-273.
4. Kahan BD, Shaw LM, Holt D, Grevel J, Johnston A. Consensus document: Hawk's Cay meeting on therapeutic drug monitoring of cyclosporine. Clin Chem 1990;36:1510-1516.
5. Holt DW, Johnston A, Roberts NB, Tredger JM, Trull AK. Methodological and clinical aspects of cyclosporin monitoring: report of the Association of Clinical Biochemists task force. Ann Clin Biochem 1994;31:420-46.
6. Holt DW, Mueller EA, Kovarik JM, van Bree JB, Kutz K. The pharmocokinetics of Sandimmun Neoral (Novartis): a new oral formulation of cyclosporine. Transplant Proc 1994;26:2935-9.
7. Holt DW, Mueller EA, Kovarik JM, van Bree JB, Richard F, Kutz K. Sandimmun Neoral (Novartis): pharmacokinetics: impact of a new oral formulation. Transplant Proc 1994;27:1434-7.
8. Food and Drug Administration. Bioavailability and hioequivalence requirements. Federal Register 1992:17997-18001.
9. Committee for Proprietary Medicinal Products. Note for guidance. Investigation of bioavailability and bioequivalence. III/54/89.
10. Mueller EA, Kovarik JM, van Bree JB, Tetzloff W, Grevel J, Kutz K. Improved dose linearity of cyclosporin pharmacokinetics from a microemulsion formulation. Pharm Res 1994;11:301-305.
11. Mueller EA, Kovarik JM, van Bree JB, Lison AE, Kutz K. Pharmacokinetics and tolerability of a microemulsion formulation of cyclosporine in renal allograft recipients: a concentration-controlled comparison with the commercial formulation. Transplantation 1994;57:1178-1182.
12. Kovarik JM, Mueller EA, van Bree JB, Fluckiger SS, Lange H, Schmidt B, Boesken WH, Lison AE, Kutz K. Cyclosporine pharmacokinetics and variability from a microemulsion formulation: a multicenter investigation in kidney transplant patients. Transplantation 1994;58:658-663.
13. Neumayer HH, Farber L, Haller P, et al. Substitution of conventional cyclosporin with a new microemulsion formulation in renal transplant patients: results after 1 year. Nephrol Dial Transplant 1996;11:165-72.
14. Johnston A, Reynold L, Wright DL, Meara M, Murday A, Holt DW. Pharmacokinetics of cyclosporin in heart transplant patients after administration of Sandimmun®. Ther Drug Monit 1995;17: 415.
15. Taesch S, Neise D. Safety and tolerability of a new oral formulation of cyclosporin A. Sandimmun Neoral (Novartis), in renal transplant patients. Transpl Int 1994;7(suppl 1):S263-S266.
16. Niese D. A double-blind randomized study of Sandimmun Neoral (Novartis) versus Sandimmun in new renal transplant recipients: results after 12 months. The International Sandimmun Neoral (Novartis) Study Group. Transplant Proc 1995;27:1849-1856.
17. Reymond JP, Steimer JL, Niederberger W. On the dose dependency of cyclosporin A absorption and disposition in healthy volunteers. J Pharmacokinet Biopharm 16:331-353.
18. Anderson JE, Munday AS, Kelman AW, et al. Evaluation of a Bayesian approach to the pharmacokinetic interpretation of cyclosporin concentrations in renal allograft recipients. Ther Drug Monit 1994;47:61-65.
19. Jacqz-Aigrain E, Montes C, Brun P, Loirat C. Cyclosporine pharmacokinetics in nephrotic and kidney-transplanted children. Eur J Clin Pharmacol 1994;47:61-65.
20. Humbert H, Guest G, Said MB, et al. Steady-state pharmacokinetics of cyclosporine in renal transplant patients: does an influence of age or body weight exist? Transplant Proc 1994;26:2791-2797.
21. Whitington PF, Emond JC, Whitington SH, Broelsch CE, Baker AL. Small-bowel length and the dose of cyclosporine in children after liver transplantation. N Engl J Med 1990;322:733-738.
22. Studies N105 & N106, Bill Sallas.
23. Honcharik N. The effect of food on cyclosporine absorption. Clin Biochem 1991;24:89-92.
24. Honcharik N, Yatscoff RW, Jeffery JR, Rush DN. The effect of meal composition on cyclosporin absorption. Transplantation 1991;52:1087-1089.
25. Mueller EA, Kovarik JM, van Bree JB, Grevel J, Lucker PW, Kutz K. Influence of a fat-rich meal on the pharmacokinetics of a new oral formulation of cyclosporine in a crossover comparison with the market formulation. Pharm Res 1994;11:151-155.
26. Ericzon BG, Todo S, Lynch S, et al. Role of bile and bile salts on cyclosporine absorption in dogs. Transplant Proc 1987;19: 1248-1249.
27. Sokol RJ, Johnson KE, Karrer FM, Narkewicz MR, Smith D, Kam I. Improvement of cyclosporin absorption in children after liver transplantation by means of water-soluble vitamin E. Lancet 1991; 338:212-215.
28. Shriner DA, Yee GC, Salomon DR, Van Sickler JT, Sacks N, Shaw LM. Influence of dietary fat and bile salts on oral cyclosporine absorption in renal transplant patients. Pharmacotherapy 1991; 11:277.
29. Campana C, Regazzi MB, Buggia I, Molinaro M. Clinically significant drug interactions with cyclosporin: and update. Clin Pharmacokinet 1996;30(2):141-179.
30. Yee GC, Stanley DL, Pessa LJ, et al. Effect of grapefruit juice on blood cyclosporin concentration. Lancet 1995;345:955-6.
31. Wadhwa NK, Schroeder TJ, O'Flaherty E, Pesce AJ, Myre SA, First MR. The effect of oral metoclopramide on the absorption of cyclosporine. Transplant Proc 1987;19:11730-11733.
32. Gupta SK, Bakran A, Johnson RWG, Rowland M. Erythromycin enhances the absorption of cyclosporin. Br J Clin Pharmacol 1988; 25:401-402.
33. Ducharme MP, Warbasse LH, Edwards DJ. Disposition of intravenous and oral cyclosporine after administration with grapefruit juice. Clin Pharmacol Ther 1995;57:485-491.
34. Clardy CW, Schroeder TJ, Myre SA, et al. Clinical variability of cyclosporine pharmacokinetics in adult and pediatric patients after renal, cardiac, hepatic and bone-marrow transplants. Clin Chem 1988;34:2012-2015.
35. Mehta MU, Venkataramanan R, Burckarart GJ, et al. Effect of bile on cyclosporin absorption in liver transplantation. Br J Clin Pharmacol 1988;25:579-584.
36. Atkinson K, Biggs JC, Britton K, et al. Oral administration of cyclosporin A for recipients of allogenic marrow transplants: implications of clinical gut dysfunction. Br J Haematol 1984;56:223-231.
37. Tan KKC, Hue KL, Strickland SE, et al. Altered pharmacokinetics of cyclosporin in heart-lung transplant recipients with cystic fibrosis. Ther Drug Monit 1990;12:520-524.
38. Altraif I, Levy G, Grant D. Pharmacokinetic studies of Sandimmune® Neoral (Novartis)® versus Sandimmune® in liver transplant recipients. Hepatology 1993;18:747.
39. Trull AK, Tan KKC, Uttridge JA, Bauer T, Alexander GJM, Jamieson NV. Cyclosprin absorption from microemulsion formulation in liver transplant recipients. Lancet 1993;341:433.
40. Ferrea G, Fioredda F, Loy A, Mangraviti S, Rossi G, Bassetti D. Oral microemulsion formulation substitutes for intravenous cyclosporin in child with graft-versus-host disease. Lancet 1994;344: 480-481.
41. Lin CY, Lee SF. Comparison of pharmacokinetics between CsA capsules and Sandimmun Neoral (Novartis) in pediatric patients. Transplant Proc 1994;26:2973-2974.
42. Tan KKC, Trull AK, Uttridge JA, Wallwork J. Relative bioavailability of cyclosporin from conventional and microemulsion formulations in heart-lung transplant candidates with cystic fibrosis. Eur J Clin Pharmacol 1995;48:285-289.
43. Nation RL, Sansom LN. Bioequivalence requirements for generic products. Pharmacol Ther 1994;62:41-55.
44. Kahan BD. Neoral (Novartis)™ addresses two limitations of existing cyclosporine formulations: limited and variable drug absorption. In: Burke JF, Kahan BD, Pollak R, Frei U, Jamieson NV, Keown PA. Neoral (Novartis)™: The new microemulsion formulation of cyclosporine. New Jersey: Published World Medical Press, 1995:12-18.
45. Inoue S, Beck Y, Nagao T, Uchida H. Early fluctuation in cyclosporine A trough levels affects long-term outcome of kidney transplants. Transplant Proc 1994;26(5):2571-2573.
46. Best NG, Trull AK, Tan KKC, et al. Blood eyclosporin concentrations and the short-term risk of lung rejection following heart-lung transplantation. Br J Clin Pharmacol 1992;34:513-520.
47. Kovarik JM, Mueller EA, van Bree JB, Tetzloff W, Kutz K. Reduced inter- and intraindividual variability in cyclosporine pharmacokinetics from a microemulsion formulation. J Pharm Sci 1994;83:444-446.
48. Kovarik JM, Mueller EA, van Bree JB, Arns W, Renner E, Kutz K. Within-day consistency in cyclosporine pharmacokinetics from a microemulsion formulation in renal transplant patients. Ther Drug Monit 1994;16:232-237.
49. Lindenbaum J, Mellow MH, Blackstone MO, Butler VP. N Engl J Med 1971;24:1344.
50. Marzo A, Balant LP. Bioequivalence: an updated reappraisal addressed to applications of interchangeable multi-source pharmaceutical products. Arzneimittelforschung 1995;45:109-115.
51. Marzo A. Open questions in bioequivalence. Pharmacol Res 1995; 32:237-240.
52. Boddy AW, Snikeris FC, Kringle RO, Wei GCG, Opperman JA, Midha KK. An approach for widening the bioequivalence acceptance limits in the case of highly variable drugs. Pharm Res 1995; 12:1865-1868.
53. Levy G. The clay feet of bioequivalence testing. J Pharm Pharmacol 1995;47:975-977.
54. McCormick PA, Hughes JE, Burroughs AK, McIntyre N. Reformation of injectable vitamin A: potential problems. BMJ 1990; 301:924.
55. Mikati M, Bassett N, Schachter S. Double-blind randomised study comparing brand-name and generic phenytoin monotherapy. Epilepsia 1992;33:359-365.
56. Hendeles L, Hochaus G, Kazerounian S. Generic and alternative brand-name pharmaceutical equivalents: select with caution. Am J Hosp Pharm 1993;50:323-329.
57. Meyer MC, Straughn AB. Biopharmaceutical factors in seizure control and drug toxicity. Am J Hosp Pharm 1993;50(suppl. 5):S17-S22.
58. Welborn MW, Connelly JF. Are Proventil Repetabs and Volmax therapeutically equivalent? Am J Health Syst Pharm 1995;52:798-801.
59. Garbe E, Röhmel J, Gundert-Remy U. Clinical and statistical issues in therapeutic equivalence trials. Eur J Clin Pharmacol 1993; 45:1-7.
60. Friman S, Bäckman L. A new microemulsion formulation of cyclosporin. Clin Pharmacokin 1996;30:181.
61. Johnston A. Factors that influence chronic rejection with cyclosporin. In: Optimising outcome in transplantation. Richmond, UK: The Workhouse, 1996.
62. WHO Expert Committee on Specifications for Pharmaceutical Preparations. WHO technical report series 863. Geneva: WHO, 1996.
63. Elder CA, Moore M, Chang CT, et al. Efficacy and pharmacokinetics of two formulations of cyclosporine A in patients with psoriasis. J Clin Pharmacol 1995;35:865-875.
64. Keown P, Lawen JG, Landsberg D, et al. Economic analysis of sandimmune Neoral (Novartis) in Canada in stable renal transplant patients. Transplant Proc 1995;27:1845-1848.
65. Steinijans VW, Hartman M, Huber R, Radtke HW. Lack of pharmacokinetic interaction as an equivalence problem. Int J Clin Pharmacol Ther Toxicol 1990;28:72-80.